Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review
Diabetes/Metabolism Research and Reviews · 2025-09 · 41 (6)
DOI: 10.1002/dmrr.70077 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 23.08.2025. Verfasst von Hongli Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetic Nephropathies, Medicine, Chinese Traditional. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 125 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, Shanghai Science and Technology Innovation Action Plan.
Abstract (Originalsprache)
Diabetic kidney disease (DKD), affecting 20–40% of individuals with diabetes, is the leading cause of end‐stage renal disease and represents a considerable global public health challenge owing to its high morbidity and mortality rates. Although traditional DKD management has focused on renin‐angiotensin system blockade, the residual risk of renal failure persists despite optimised therapy. New therapeutic drugs, including glucagon‐like peptide‐1 receptor agonists, have triggered a paradigm shift in DKD treatment. Sodium‐glucose cotransporter‐2 inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and selective endothelin receptor antagonists have shown notable efficacy in improving renal outcomes in patients with type 2 diabetes mellitus. Furthermore, traditional Chinese medicine (TCM), with its holistic approach and evidence‐based refinements, has shown considerable promise in DKD treatment, particularly as its theoretical framework continues to evolve. This study highlighted the transformative potential of multitargeted strategies in mitigating DKD progression, improving cardiovascular outcomes, and alleviating healthcare burdens. Future research should prioritise standardised trials, long‐term safety assessments of TCM and personalised therapeutic regimens to optimise clinical management and patient quality of life.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Clinical Nutrition, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Multiscale Research Institute of Complex Systems, Fudan University, Shanghai, China.
- Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Taipa, Macao, China.
Förderung
- Science and Technology Commission of Shanghai Municipality
- Shanghai Science and Technology Innovation Action Plan
Zitieren
APA
Zhang, H., Chen, J., Wang, N., Chen, W., Xu, Y., & Gui, D. (2025). Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review. Diabetes/Metabolism Research and Reviews, 41(6). https://doi.org/10.1002/dmrr.70077
Vancouver
Zhang H, Chen J, Wang N, Chen W, Xu Y, Gui D. Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review. Diabetes/Metabolism Research and Reviews. 2025;41(6). doi:10.1002/dmrr.70077
BibTeX
@article{Zhang2025,
author = {Zhang, Hongli and Chen, Jiewen and Wang, Niansong and Chen, Wei and Xu, Youhua and Gui, Dingkun},
title = {Advancements in Pharmacotherapy for Diabetic Kidney Disease: A Systematic Review},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2025},
volume = {41},
number = {6},
doi = {10.1002/dmrr.70077}
}
EUVIMED